128 related articles for article (PubMed ID: 37116527)
1. Clinical impact of syndromic molecular point-of-care testing for gastrointestinal pathogens in adults hospitalised with suspected gastroenteritis (GastroPOC): a pragmatic, open-label, randomised controlled trial.
Brendish NJ; Beard KR; Malachira AK; Tanner AR; Sanga-Nyirongo L; Gwiggner M; Cummings JRF; Moyses HE; Clark TW
Lancet Infect Dis; 2023 Aug; 23(8):945-955. PubMed ID: 37116527
[TBL] [Abstract][Full Text] [Related]
2. Clinical impact of a routine, molecular, point-of-care, test-and-treat strategy for influenza in adults admitted to hospital (FluPOC): a multicentre, open-label, randomised controlled trial.
Clark TW; Beard KR; Brendish NJ; Malachira AK; Mills S; Chan C; Poole S; Ewings S; Cortes N; Nyimbili E; Presland L
Lancet Respir Med; 2021 Apr; 9(4):419-429. PubMed ID: 33285143
[TBL] [Abstract][Full Text] [Related]
3. Molecular point-of-care testing for lower respiratory tract pathogens improves safe antibiotic de-escalation in patients with pneumonia in the ICU: Results of a randomised controlled trial.
Poole S; Tanner AR; Naidu VV; Borca F; Phan H; Saeed K; Grocott MPW; Dushianthan A; Moyses H; Clark TW
J Infect; 2022 Dec; 85(6):625-633. PubMed ID: 36096312
[TBL] [Abstract][Full Text] [Related]
4. Routine molecular point-of-care testing for respiratory viruses in adults presenting to hospital with acute respiratory illness (ResPOC): a pragmatic, open-label, randomised controlled trial.
Brendish NJ; Malachira AK; Armstrong L; Houghton R; Aitken S; Nyimbili E; Ewings S; Lillie PJ; Clark TW
Lancet Respir Med; 2017 May; 5(5):401-411. PubMed ID: 28392237
[TBL] [Abstract][Full Text] [Related]
5. Routine molecular point-of-care testing for SARS-CoV-2 reduces hospital-acquired COVID-19.
Livingstone R; Lin H; Brendish NJ; Poole S; Tanner AR; Borca F; Smith T; Stammers M; Clark TW
J Infect; 2022 Apr; 84(4):558-565. PubMed ID: 35108599
[TBL] [Abstract][Full Text] [Related]
6. Clinical impact of molecular point-of-care testing for suspected COVID-19 in hospital (COV-19POC): a prospective, interventional, non-randomised, controlled study.
Brendish NJ; Poole S; Naidu VV; Mansbridge CT; Norton NJ; Wheeler H; Presland L; Kidd S; Cortes NJ; Borca F; Phan H; Babbage G; Visseaux B; Ewings S; Clark TW
Lancet Respir Med; 2020 Dec; 8(12):1192-1200. PubMed ID: 33038974
[TBL] [Abstract][Full Text] [Related]
7. Molecular point-of-care testing for respiratory viruses versus routine clinical care in adults with acute respiratory illness presenting to secondary care: a pragmatic randomised controlled trial protocol (ResPOC).
Brendish NJ; Malachira AK; Clark TW
BMC Infect Dis; 2017 Feb; 17(1):128. PubMed ID: 28166743
[TBL] [Abstract][Full Text] [Related]
8. Norwegian Coronavirus Disease 2019 (NO COVID-19) Pragmatic Open label Study to assess early use of hydroxychloroquine sulphate in moderately severe hospitalised patients with coronavirus disease 2019: A structured summary of a study protocol for a randomised controlled trial.
Lyngbakken MN; Berdal JE; Eskesen A; Kvale D; Olsen IC; Rangberg A; Jonassen CM; Omland T; Røsjø H; Dalgard O
Trials; 2020 Jun; 21(1):485. PubMed ID: 32503662
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of a molecular point-of-care testing for viral and atypical pathogens on intravenous antibiotic duration in hospitalized adults with lower respiratory tract infection: a randomized clinical trial.
Shengchen D; Gu X; Fan G; Sun R; Wang Y; Yu D; Li H; Zhou F; Xiong Z; Lu B; Zhu G; Cao B
Clin Microbiol Infect; 2019 Nov; 25(11):1415-1421. PubMed ID: 31229593
[TBL] [Abstract][Full Text] [Related]
10. Effect on mortality of point-of-care, urine-based lipoarabinomannan testing to guide tuberculosis treatment initiation in HIV-positive hospital inpatients: a pragmatic, parallel-group, multicountry, open-label, randomised controlled trial.
Peter JG; Zijenah LS; Chanda D; Clowes P; Lesosky M; Gina P; Mehta N; Calligaro G; Lombard CJ; Kadzirange G; Bandason T; Chansa A; Liusha N; Mangu C; Mtafya B; Msila H; Rachow A; Hoelscher M; Mwaba P; Theron G; Dheda K
Lancet; 2016 Mar; 387(10024):1187-97. PubMed ID: 26970721
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of point-of-care multiplex polymerase chain reaction in guiding antibiotic treatment of patients acutely admitted with suspected community-acquired pneumonia in Denmark: A multicentre randomised controlled trial.
Cartuliares MB; Rosenvinge FS; Mogensen CB; Skovsted TA; Andersen SL; Østergaard C; Pedersen AK; Skjøt-Arkil H
PLoS Med; 2023 Nov; 20(11):e1004314. PubMed ID: 38015833
[TBL] [Abstract][Full Text] [Related]
12. Point-of-care C-reactive protein testing to reduce inappropriate use of antibiotics for non-severe acute respiratory infections in Vietnamese primary health care: a randomised controlled trial.
Do NT; Ta NT; Tran NT; Than HM; Vu BT; Hoang LB; van Doorn HR; Vu DT; Cals JW; Chandna A; Lubell Y; Nadjm B; Thwaites G; Wolbers M; Nguyen KV; Wertheim HF
Lancet Glob Health; 2016 Sep; 4(9):e633-41. PubMed ID: 27495137
[TBL] [Abstract][Full Text] [Related]
13. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
[TBL] [Abstract][Full Text] [Related]
14. Multiplex tests to identify gastrointestinal bacteria, viruses and parasites in people with suspected infectious gastroenteritis: a systematic review and economic analysis.
Freeman K; Mistry H; Tsertsvadze A; Royle P; McCarthy N; Taylor-Phillips S; Manuel R; Mason J
Health Technol Assess; 2017 Apr; 21(23):1-188. PubMed ID: 28619124
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of antimicrobial stewardship prospective audit and feedback in patients hospitalised with COVID-19 (COVASP): a pragmatic, cluster-randomised, non-inferiority trial.
Chen JZ; Hoang HL; Yaskina M; Kabbani D; Doucette KE; Smith SW; Lau C; Stewart J; Remtulla S; Zurek K; Schultz M; Koriyama-McKenzie H; Cervera C
Lancet Infect Dis; 2023 Jun; 23(6):673-682. PubMed ID: 36716763
[TBL] [Abstract][Full Text] [Related]
16. Procalcitonin testing to guide antibiotic therapy for the treatment of sepsis in intensive care settings and for suspected bacterial infection in emergency department settings: a systematic review and cost-effectiveness analysis.
Westwood M; Ramaekers B; Whiting P; Tomini F; Joore M; Armstrong N; Ryder S; Stirk L; Severens J; Kleijnen J
Health Technol Assess; 2015 Nov; 19(96):v-xxv, 1-236. PubMed ID: 26569153
[TBL] [Abstract][Full Text] [Related]
17. Pragmatic multicentre randomised controlled trial evaluating the impact of a routine molecular point-of-care 'test-and-treat' strategy for influenza in adults hospitalised with acute respiratory illness (FluPOC): trial protocol.
Beard K; Brendish N; Malachira A; Mills S; Chan C; Poole S; Clark T
BMJ Open; 2019 Dec; 9(12):e031674. PubMed ID: 31852699
[TBL] [Abstract][Full Text] [Related]
18. Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial.
Ader F; Bouscambert-Duchamp M; Hites M; Peiffer-Smadja N; Poissy J; Belhadi D; Diallo A; Lê MP; Peytavin G; Staub T; Greil R; Guedj J; Paiva JA; Costagliola D; Yazdanpanah Y; Burdet C; Mentré F;
Lancet Infect Dis; 2022 Feb; 22(2):209-221. PubMed ID: 34534511
[TBL] [Abstract][Full Text] [Related]
19. A pilot randomised controlled trial in intensive care patients comparing 7 days' treatment with empirical antibiotics with 2 days' treatment for hospital-acquired infection of unknown origin.
Scawn N; Saul D; Pathak D; Matata B; Kemp I; Stables R; Lane S; Haycox A; Houten R
Health Technol Assess; 2012 Sep; 16(36):i-xiii, 1-70. PubMed ID: 23010339
[TBL] [Abstract][Full Text] [Related]
20. Coagulopathy of hospitalised COVID-19: A Pragmatic Randomised Controlled Trial of Therapeutic Anticoagulation versus Standard Care as a Rapid Response to the COVID-19 Pandemic (RAPID COVID COAG - RAPID Trial): A structured summary of a study protocol for a randomised controlled trial.
Sholzberg M; Tang GH; Negri E; Rahhal H; Kreuziger LB; Pompilio CE; James P; Fralick M; AlHamzah M; Alomran F; Tseng E; Lim G; Lillicrap D; Carrier M; Áinle FN; Beckett A; da Costa BR; Thorpe K; Middeldorp S; Lee A; Cushman M; Jüni P
Trials; 2021 Mar; 22(1):202. PubMed ID: 33691765
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
